49. Radionuclide therapy of neuroendocrine and neuroectodermal tumors.

From greek.doctor
Revision as of 21:10, 4 January 2024 by Nikolas (Sọ̀rọ̀ | contribs) (Created page with "* '''Neuroendocrine (carcinoid) tumors express somatostatin receptors -> radiopharmaceuticals will bind to these receptors''' ** '''Indications''' *** Lung neuroendocrine tumors *** Adenocarcinomas of GI tract and pancreas ** '''Radiopharmaceuticals which bind to SST receptors''' *** '''111In-octreotide – indium-111-octreotide''' *** 99mTc-depreotide * '''I123-MIBG scintigraphy''' ** '''I123-MIBG binds to adrenergic receptors in neuroendocrine tumors''' ** Indications...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
  • Neuroendocrine (carcinoid) tumors express somatostatin receptors -> radiopharmaceuticals will bind to these receptors
    • Indications
      • Lung neuroendocrine tumors
      • Adenocarcinomas of GI tract and pancreas
    • Radiopharmaceuticals which bind to SST receptors
      • 111In-octreotide – indium-111-octreotide
      • 99mTc-depreotide
  • I123-MIBG scintigraphy
    • I123-MIBG binds to adrenergic receptors in neuroendocrine tumors
    • Indications
      • Neuroblastoma
      • Phaeochromocytoma
    • Thyroid must be protected from radiation
      • Iodine is given before examination